Upstream Bio, Inc. (UPB) Stock Analysis & Investment Frameworks
Upstream Bio, Inc. (UPB) stock analysis on Invetso. Review Upstream Bio, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Upstream Bio, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
Upstream Bio, Inc. Key Financial Metrics
- Market Cap: $150.07M
- Revenue: $2.85M
- ROE: -48.40%
- ROIC: -62.51%
- Dividend Yield: N/A
About Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.